Michael Giordano
Director/Board Member bij RAPT THERAPEUTICS, INC.
Vermogen: 61 595 $ op 29-02-2024
Profiel
Michael F.
Giordano is on the board of Rapt Therapeutics, Inc., Achilles Therapeutics UK Ltd., Achilles Therapeutics Plc and Oncovalent Therapeutics, Inc.
In his past career he was Senior Vice President & Head-Oncology Development at Bristol Myers Squibb Co., Director at Epizyme, Inc., Assistant Professor at National Institutes of Health and Assistant Professor at Weill Cornell Medicine.
Michael F.
Giordano received an undergraduate degree from The Johns Hopkins University and a doctorate from Weill Cornell Medicine.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
01-02-2023 | 46 663 ( 0.11% ) | 61 595 $ | 29-02-2024 | |
RAPT THERAPEUTICS, INC.
-.--% | 24-05-2023 | 0 ( -.--% ) | - $ | 29-02-2024 |
Actieve functies van Michael Giordano
Bedrijven | Functie | Begin |
---|---|---|
RAPT THERAPEUTICS, INC. | Director/Board Member | 01-01-2018 |
ACHILLES THERAPEUTICS PLC | Director/Board Member | - |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Director/Board Member | 19-09-2018 |
Oncovalent Therapeutics, Inc.
Oncovalent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncovalent Therapeutics, Inc. develops immuno oncology drugs and therapeutics. The company is based in Thousand Oaks, CA. Pete Feldman has been the CEO of the company since 2020. | Director/Board Member | - |
Eerdere bekende functies van Michael Giordano
Bedrijven | Functie | Einde |
---|---|---|
EPIZYME, INC. | Chief Tech/Sci/R&D Officer | 01-08-2018 |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01-02-2017 |
Weill Cornell Medicine | Corporate Officer/Principal | - |
National Institutes of Health
National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Corporate Officer/Principal | - |
Opleiding van Michael Giordano
The Johns Hopkins University | Undergraduate Degree |
Weill Cornell Medicine | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
RAPT THERAPEUTICS, INC. | Health Technology |
ACHILLES THERAPEUTICS PLC | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
National Institutes of Health
National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Government |
Epizyme, Inc.
Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Oncovalent Therapeutics, Inc.
Oncovalent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncovalent Therapeutics, Inc. develops immuno oncology drugs and therapeutics. The company is based in Thousand Oaks, CA. Pete Feldman has been the CEO of the company since 2020. | Health Technology |